Company Medicenna Therapeutics Corp.

Equities

MDNA

CA58490H1073

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research

Delayed Toronto S.E. Other stock markets 02:57:00 2024-04-24 pm EDT			5-day change	1st Jan Change
1.88 ^CAD	+21.29%		+8.67%	+347.62%

04:48pm	Medicenna Therapeutics Up 13% After Flagging Presentations	MT
Apr. 16	Transcript : Medicenna Therapeutics Corp. Presents at Bloom Burton & Co. Healthcare Investor Conference 2024, Apr-16-2024 11:00 AM

Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Companyâs IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Companyâs early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.

Number of employees: 16

Managers	Title	Age	Since
Rosemina Merchant FOU	Founder	-	11-09-30
Fahar Merchant CEO	Chief Executive Officer	-	15-02-01
David Hyman DFI	Director of Finance/CFO	-	Feb. 13
Delphine Davan IRC	Investor Relations Contact	-	23-08-13
Minh To PRN	Corporate Officer/Principal	-	23-08-13
Eamonn Peters PRN	Corporate Officer/Principal	-	23-08-13
Evelyn Pau PRN	Corporate Officer/Principal	-	23-08-13

Members of the board	Title	Age	Since
Karen Dawes BRD	Director/Board Member	72	19-09-23
Albert Beraldo BRD	Director/Board Member	-	16-11-21
Fahar Merchant CEO	Chief Executive Officer	-	15-02-01
Rosemina Merchant FOU	Founder	-	11-09-30
Jack Geltosky BRD	Director/Board Member	78	20-09-29
John Sampson BRD	Director/Board Member	-	21-09-22

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	69,637,469	48,558,694 ( 69.73 %)	0	69.73 %

Name	Equities	%	Valuation
Aries Biologics, Inc. 7.898 %	5,500,000	7.898 %	8 M $
Fahar Merchant 7.612 %	5,300,700	7.612 %	7 M $
Rosemina Merchant 7.612 %	5,300,700	7.612 %	7 M $
AIGH Capital Management LLC 6.709 %	4,672,075	6.709 %	6 M $
Albert Beraldo 0.4667 %	325,000	0.4667 %	445 250 $
Next Edge Capital Corp. 0.3375 %	235,000	0.3375 %	321 950 $
RATHBONES GROUP PLC 0.1517 %	105,663	0.1517 %	144 758 $
Karen Dawes 0.0359 %	25,000	0.0359 %	34 250 $
David Hyman 0.0287 %	20,000	0.0287 %	27 400 $
David Hyman 0.0287 %	20,000	0.0287 %	27 400 $

Medicenna Therapeutics Corp.

2 Bloor Street West 7th floor

M4W 3E2, Toronto

http://www.medicenna.com

address Medicenna Therapeutics Corp.(MDNA)

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.55 CAD

Average target price

9 CAD

Spread / Average Target

+480.65%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Other Biotechnology & Medical Research

	1st Jan change	Capi.
MEDICENNA THERAPEUTICS CORP.	+347.62%	78.95M
IQVIA HOLDINGS INC.	+3.83%	43.43B
LONZA GROUP AG	+47.81%	41.69B
MODERNA, INC.	+8.94%	41.31B
CELLTRION, INC.	-10.92%	27.14B
ICON PUBLIC LIMITED COMPANY	+8.46%	25.28B
ALNYLAM PHARMACEUTICALS, INC.	-24.76%	18.47B
MEDPACE HOLDINGS, INC.	+29.16%	12.59B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	+1.10%	12.33B
UNITED THERAPEUTICS CORPORATION	+8.66%	11.03B

Other Biotechnology & Medical Research